



(12) Translation of
European patent specification

(11) NO/EP 2367570 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.03.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.12.20
(86)	European Application Nr.	09830697.0
(86)	European Filing Date	2009.11.24
(87)	The European Application's Publication Date	2011.09.28
(30)	Priority	2008.11.25, US, 117811 P 2008.11.25, US, 117839 P 2008.11.25, US, 117861 P 2009.02.05, US, 366567 2009.02.24, US, 391615 2009.02.24, US, 391717 2009.03.06, US, 399156 2009.07.14, US, 502581
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	AlderBio Holdings LLC, 101 Convention Center Drive, Suite 850, Las Vegas, NV 89109, US-USA
(72)	Inventor	GARCIA - MARTINEZ, Leon, 4926 214th Street, S.E., Woodinville, WA 98072, US-USA CARVALHO-JENSEN, Anne Elisabeth, 12303 Harbour Pointe Blvd., Mukilteo, WA 98725, US-USA OLSON, Katie, 6700 NE 182nd Street D207, Kenmore, WA 98028, US-USA DUTZAR, Ben, 2422 Dexter Avenue N., 103, Seattle, WA 98109, US-USA LATHAM, John, 2409 10th Avenue, Seattle, WA 98119, US-USA KOVACEVICH, Brian, 13916 233rd Street, SE, Snohomish, WA 98296, US-USA SMITH, Jeffrey T.L., 10270 N.E. 12th St., Apt. F307, Bellevue, WA 98004, US-USA LITTON, Mark, 913 W. Raye Street, Seattle, WA 98119, US-USA SCHATZMAN, Randall, 5733 238th Place, NE, Redmond, WA 98053, US-USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **ANTIBODIES TO IL-6 AND USE THEREOF**

(56) References

Cited:

WO-A1-2004/039826, VAN ZAAANEN H C T ET AL: "Endogenous interleukin 6 production in multiple myeloma patients treated with himeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 98, no. 6, 1 September 1996 (1996-09-01), pages 1441-1448, XP008092204, ISSN: 0021-9738, DOI: 10.1172/JCI118932, WO-A2-2008/065378, WO-A2-2008/144763, US-A1- 2003 219 839, US-A1- 2004 014 658, US-A1- 2007 280 941, US-A1- 2007 292 420, US-A1- 2008 075 726, US-B1- 6 709 660, US-B2- 7 345 217, US-B2- 7 431 927, MATSUYAMA MASASHI ET AL: "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, TOKYO, JP; BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 January 2007 (2007-01-01), pages 771-774, XP002696891, ISSN: 0918-2918, DOI: 10.2169/INTERNALMEDICINE.46.6262, EMILLE D ET AL: "ADMINISTRATION OF AN ANTI-INTERLEUKIN-6 MONOCLONAL ANTIBODY TO PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND LYMPHOMA: EFFECT ON LYMPHOMA GROWTH AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 84, no. 8, 15 October 1994 (1994-10-15), pages 2472-2479, XP001088120, ISSN: 0006-4971, M. H. ZAKI ET AL: "Proc Am Soc Clin Oncol", 2003 ASCO ANNUAL MEETING - DEVELOPMENTAL THERAPEUTICS - CLINICAL PHARMACOLOGY AND IMMUNOTHERAPY, vol. 22, 697, 2003, XP055045899, Retrieved from the Internet: URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100701 [retrieved on 2012-11-27], BATAILLE R ET AL: "Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 86, no. 2, 15 July 1995 (1995-07-15), pages 685-691, XP002448659, ISSN: 0006-4971, G STRASSMANN ET AL: "Evidence for the involvement of interleukin 6 in experimental cancer cachexia.", JOURNAL OF CLINICAL INVESTIGATION, vol. 89, no. 5, 1 May 1992 (1992-05-01), pages 1681-1684, XP055045903, ISSN: 0021-9738, DOI: 10.1172/JCI115767, STRASSMANN G ET AL: "INHIBITION OF EXPERIMENTAL CANCER CACHEXIA BY ANTI-CYTOKINE AND ANTI-CYTOKINE-RECEPTOR THERAPY", CYTOKINES AND MOLECULAR THERAPY, DUNITZ, LONDON, GB, vol. 1, no. 2, 1 January 1995 (1995-01-01), pages 107-113, XP008043222, ISSN: 1355-6568, KLEIN ET AL: "Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.", BLOOD, vol. 78, no. 5, 1 September 1991 (1991-09-01), pages 1198-1204, XP055045905, ISSN: 0006-4971, KAORI FUJIMOTO-OUCHI ET AL: "Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 59, no. 6, 29 September 2006 (2006-09-29), pages 807-815, XP019490080, ISSN: 1432-0843, SUMIE TAMURA ET AL: "Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft.", CLINICAL CANCER RESEARCH, vol. 1, 1 January 1995 (1995-01-01), pages 1353-1358, XP055045909, Thomson Reuters - Integrity: "Humanized Anti-IL-6 monoclonal antibody-Heavy and light chains", 16 January 2008 (2008-01-16), XP055292638, Retrieved from the Internet: URL:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_id=468410 [retrieved on 2016-08-01], ZAKI M H ET AL: "CNTO 328, A monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 111, 1 January 2004 (2004-01-01), pages 592-595, XP003012697, ISSN: 0020-7136, DOI: 10.1002/IJC.20270, TRIKHA MOHIT ET AL: "Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 13, 1 January 2003 (2003-01-01), pages 4653-4665, XP002543280, ISSN: 1078-0432, VAN ZAAANEN H C T ET AL: "Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 102, 1 January 1998 (1998-01-01), pages 783-790, XP002986057, ISSN: 0007-1048, DOI: 10.1046/J.1365-2141.1998.00835.X, WO-A2-2004/078938

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Sammensetning omfattende et anti-IL-6 antistoff som omfatter et lettkjede polypeptid som omfatter polypeptidet ifølge SEKV ID NR: 709, og lettkjede konstant regionen med SEKV ID NR: 586, og et tungkjede polypeptid som omfatter polypeptidet ifølge SEKV ID NR: 657 og tungkjede konstant regionen med SEKV ID NR: 588, hvori anti-IL-6 antistoff er aglykosylert.
5
2. Sammensetning ifølge et hvilket som helst av de foregående krav, for anvendelse i en fremgangsmåte for å forebygge, behandle eller detektere fremskreden kreft og/eller reumatoid artritt.
10
3. Sammensetning for anvendelse ifølge krav 3, hvori sammensetningen er for anvendelse i et humant terapeutisk regime for behandling av reumatoid artritt.
15
4. Sammensetning for anvendelse ifølge krav 3 eller 4, hvori anti-IL-6 antistoff sammensetningen er for anvendelse i human terapi:
 - (i) en gang per periode på omtrent fire uker;
 - (ii) en gang per periode på omtrent åtte uker;
 - (iii) en gang per periode på omtrent tolv uker;
 - (iv) en gang per periode på omtrent seksten uker.
20
5. Sammensetning ifølge krav 1 eller 2, eller sammensetning for anvendelse ifølge hvilket som helst av kravene 3-5, hvori anti-IL-6 antistoffet omfatter et lettkjede polypeptid som omfatter polypeptidet ifølge SEKV ID NR: 704 og et tungkjede polypeptid som omfatter polypeptidet ifølge SEKV ID NR: 702.
25